$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

$gthp Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000147793222001704 Filed on March 30, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$60.00K	$19.00K	$81.00K
YoY Change	140.0%	-75.32%	-20.59%
Cost Of Revenue	$19.00K	$42.00K	$61.00K
YoY Change	-131.67%	250.0%	-248.78%
Gross Profit	$41.00K	-$23.00K	$20.00K
YoY Change	-51.76%	-135.38%	-86.01%
Gross Profit Margin	68.33%	-121.05%	24.69%
Selling, General & Admin	$459.0K	$448.0K	$2.313M
YoY Change	30.77%	153.11%	119.87%
% of Gross Profit	1119.51%		11565.0%
Research & Development	$17.00K	$16.00K	$69.00K
YoY Change	-15.0%	-60.98%	-51.75%
% of Gross Profit	41.46%		345.0%
Depreciation & Amortization	$0.00	$1.000K	$1.000K
YoY Change
% of Gross Profit	0.0%		5.0%
Operating Expenses	$476.0K	$464.0K	$2.382M
YoY Change	27.61%	112.84%	99.33%
Operating Profit	-$435.0K	-$487.0K	-$2.362M
YoY Change	51.04%	218.3%	124.52%
Interest Expense	-$102.0K	$594.0K	$1.150M
YoY Change	-104.57%	87.38%	8.9%
% of Operating Profit
Other Income/Expense, Net	$93.00K	$555.0K	$292.0K
YoY Change	-57.73%	-67.88%	-62.23%
Pretax Income	-$444.0K	$68.00K	-$2.070M
YoY Change	-120.5%	-95.68%	641.94%
Income Tax		$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$444.0K	$68.00K	-$2.070M
YoY Change	-120.5%	-95.68%	641.94%
Net Earnings / Revenue	-740.0%	357.89%	-2555.56%
Basic Earnings Per Share		$0.00	-$0.18
Diluted Earnings Per Share	-$32.56K	$0.00	-$0.18
COMMON SHARES
Basic Shares Outstanding	13.63M shares	13.42M shares	13.38M shares
Diluted Shares Outstanding			13.38M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$643.0K	$541.0K	$643.0K
YoY Change	253.3%	-6.88%	253.3%
Cash & Equivalents	$643.0K	$541.0K	$643.0K
Short-Term Investments
Other Short-Term Assets	$377.0K	$173.0K	$377.0K
YoY Change	343.53%	-71.31%	343.53%
Inventory	$571.0K	$590.0K	$571.0K
Prepaid Expenses
Receivables	$46.00K	$24.00K	$46.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.637M	$1.328M	$1.637M
YoY Change	82.7%	7.27%	82.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.00K	$11.00K	$386.0K
YoY Change	1300.0%	-82.26%	-14.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.00K	$17.00K	$17.00K
YoY Change
Total Long-Term Assets	$403.0K	$416.0K	$403.0K
YoY Change	-11.23%	570.97%	-11.23%
TOTAL ASSETS
Total Short-Term Assets	$1.637M	$1.328M	$1.637M
Total Long-Term Assets	$403.0K	$416.0K	$403.0K
Total Assets	$2.040M	$1.744M	$2.040M
YoY Change	51.11%	34.15%	51.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.362M	$2.220M	$2.449M
YoY Change	-2.36%	-18.53%	-3.39%
Accrued Expenses	$1.768M	$32.95K	$1.486M
YoY Change	-40.97%	-98.89%	-51.29%
Deferred Revenue
YoY Change
Short-Term Debt	$824.0K	$861.0K	$824.0K
YoY Change	-40.16%	66.86%	-40.16%
Long-Term Debt Due	$88.00K	$18.00K	$249.0K
YoY Change	214.29%	-99.13%	-87.28%
Total Short-Term Liabilities	$5.694M	$5.076M	$5.694M
YoY Change	-36.47%	-38.88%	-36.47%
LONG-TERM LIABILITIES
Long-Term Debt	$1.434M	$1.373M	$1.434M
YoY Change	130.18%	8.62%	130.18%
Other Long-Term Liabilities	$357.0K	$373.0K	$357.0K
YoY Change	-86.37%	-93.28%	-86.37%
Total Long-Term Liabilities	$1.791M	$1.746M	$1.791M
YoY Change	-44.77%	-74.38%	-44.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.694M	$5.076M	$5.694M
Total Long-Term Liabilities	$1.791M	$1.746M	$1.791M
Total Liabilities	$7.485M	$6.822M	$7.485M
YoY Change	-38.67%	-54.88%	-38.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$142.4M	-$141.9M
YoY Change	1.74%
Common Stock	$3.403M	$3.403M
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$132.0K	$132.0K
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	-$5.445M	-$5.078M	-$5.445M
YoY Change
Total Liabilities & Shareholders Equity	$2.040M	$1.744M	$2.040M
YoY Change	51.11%	34.15%	51.11%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	-$444.0K	$68.00K	-$2.070M
YoY Change	-120.5%	-95.68%	641.94%
Depreciation, Depletion And Amortization	$0.00	$1.000K	$1.000K
YoY Change
Cash From Operating Activities	$159.0K	-$739.0K	-$1.592M
YoY Change	-148.04%	21.95%	-15.09%
INVESTING ACTIVITIES
Capital Expenditures	-$4.000K	-$5.000K	$14.00K
YoY Change			1300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$4.000K	-$5.000K	-$14.00K
YoY Change			1300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-53.00K	363.0K	$2.067M
YoY Change	-22.06%	-14.39%	78.34%
NET CHANGE
Cash From Operating Activities	159.0K	-739.0K	-$1.592M
Cash From Investing Activities	-4.000K	-5.000K	-$14.00K
Cash From Financing Activities	-53.00K	363.0K	$2.067M
Net Change In Cash	102.0K	-381.0K	$461.0K
YoY Change	-125.56%	109.34%	-164.3%
FREE CASH FLOW
Cash From Operating Activities	$159.0K	-$739.0K	-$1.592M
Capital Expenditures	-$4.000K	-$5.000K	$14.00K
Free Cash Flow	$163.0K	-$734.0K	-$1.606M
YoY Change	-149.24%	21.12%	-14.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126800000	USD
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0	USD
CY2020Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1930000	USD
CY2021Q4	gthp	Convertible Short Term Notes Payable ConvertibleShortTermNotesPayable	736000	USD
CY2020Q4	gthp	Convertible Short Term Notes Payable ConvertibleShortTermNotesPayable	951000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5694000	USD
CY2021Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2020Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	2203000	USD
CY2021	dei	Auditor Location AuditorLocation	Sterling Heights, Michigan
CY2021Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	126000	USD
CY2021Q4	gthp	Accounts Receivable Net Of Allowance For Doubtful Accounts Of126 At December312021 And2020 AccountsReceivableNetOfAllowanceForDoubtfulAccountsOf126AtDecember312021And2020	46000	USD
CY2020Q4	gthp	Accounts Receivable Net Of Allowance For Doubtful Accounts Of126 At December312021 And2020 AccountsReceivableNetOfAllowanceForDoubtfulAccountsOf126AtDecember312021And2020	24000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	785000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	758000	USD
CY2021Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	0	USD
CY2020Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	328000	USD
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	0	USD
CY2020Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	1000	USD
CY2021Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	48000	USD
CY2021Q4	gthp	Past Due Short Term Non Bank Loans And Notes Payable Related Parties Current PastDueShortTermNonBankLoansAndNotesPayableRelatedPartiesCurrent	40000	USD
CY2020Q4	gthp	Past Due Short Term Non Bank Loans And Notes Payable Related Parties Current PastDueShortTermNonBankLoansAndNotesPayableRelatedPartiesCurrent	51000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	325000	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	32000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	820000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	23000	USD
CY2021Q4	gthp	Long Term Debt Non Current LongTermDebtNonCurrent	22000	USD
CY2020Q4	gthp	Long Term Debt Non Current LongTermDebtNonCurrent	0	USD
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	592000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1791000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	7485000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13673000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13138000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3403000	USD
CY2020Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	45000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8962000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	392000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	25000	USD
CY2020Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	600000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3243000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	12205000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142387000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	123109000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139956000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5445000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10855000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2040000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1350000	USD
CY2020	us-gaap	Gross Profit GrossProfit	143000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	143000	USD
CY2021	gthp	Cost Of Goods Sold Recovered CostOfGoodsSoldRecovered	61000	USD
CY2020	gthp	Cost Of Goods Sold Recovered CostOfGoodsSoldRecovered	-41000	USD
CY2021	us-gaap	Gross Profit GrossProfit	20000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2172000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	2382000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	1195000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2362000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-1052000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1150000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1056000	USD
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-91000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2070000	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-25000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	578000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-296000	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	448000	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1879000	USD
CY2021	us-gaap	Other Income OtherIncome	507000	USD
CY2020	us-gaap	Other Income OtherIncome	271000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	292000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	773000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-279000	USD
CY2021	gthp	Preferred Stock Dividends PreferredStockDividends	-361000	USD
CY2020	gthp	Preferred Stock Dividends PreferredStockDividends	-122000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2431000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-401000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13377000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10767000	shares
CY2021	us-gaap	Weighted Average Limited Partnership Units Outstanding Diluted WeightedAverageLimitedPartnershipUnitsOutstandingDiluted	13377000	shares
CY2020	us-gaap	Weighted Average Limited Partnership Units Outstanding Diluted WeightedAverageLimitedPartnershipUnitsOutstandingDiluted	10767000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-10855000	USD
CY2021	gthp	Series F Preferred Offering SeriesFPreferredOffering	1195000	USD
CY2021	gthp	Series F2 Preferred Offering SeriesF2PreferredOffering	404000	USD
CY2021	gthp	Conversion Of Debt And Expenses For Series F2 Preferred Stock ConversionOfDebtAndExpensesForSeriesF2PreferredStock	2559000	USD
CY2021	gthp	Issuanceofcommonstocktofindersshares Issuanceofcommonstocktofindersshares	98000	shares
CY2021	gthp	Issuance Of Common Stock To Finders Amount IssuanceOfCommonStockToFindersAmount	54000	USD
CY2021	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	53000	USD
CY2021	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	118000	USD
CY2021	gthp	Issuance Of Warrants To Consultants IssuanceOfWarrantsToConsultants	1172000	USD
CY2021	gthp	Warrants Issued With Debt Amount WarrantsIssuedWithDebtAmount	304000	USD
CY2021	gthp	Series G Preferred Offering SeriesGPreferredOffering	0	USD
CY2021	gthp	Conversion Of Warrants From Liabilities To Equity Amount ConversionOfWarrantsFromLiabilitiesToEquityAmount	1755000	USD
CY2021	gthp	Series G Redemption SeriesGRedemption	0	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	227000	USD
CY2021	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-361000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2070000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5445000	USD
CY2021	gthp	Conversion Of Series F Preferred Shares Into Common Stock Amount ConversionOfSeriesFPreferredSharesIntoCommonStockAmount	0	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-16935000	USD
CY2020	gthp	Issuance Of Preferred Stock In Financing Amount IssuanceOfPreferredStockInFinancingAmount	1915000	USD
CY2020	gthp	Conversion Of Debt Into Common Stock Amount ConversionOfDebtIntoCommonStockAmount	2929000	USD
CY2020	gthp	Issuance Of Common Stock In Financing Amount IssuanceOfCommonStockInFinancingAmount	461000	USD
CY2020	gthp	Issuance Of Warrants In Financing IssuanceOfWarrantsInFinancing	117000	USD
CY2020	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	40000	USD
CY2020	gthp	Beneficial Conversion Feature Of Convertible Debt BeneficialConversionFeatureOfConvertibleDebt	82000	USD
CY2020	gthp	Adjustment To Warrant Liability For Adoption Of Asu AdjustmentToWarrantLiabilityForAdoptionOfAsu	627000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	310000	USD
CY2020	gthp	Accrued Series D Preferred Stock Dividends AccruedSeriesDPreferredStockDividends	-122000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-279000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-10855000	USD
CY2021	gthp	Net Loss NetLoss	2071000	USD
CY2020	gthp	Net Loss NetLoss	279000	USD
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	0	USD
CY2020	us-gaap	Interest And Debt Expense InterestAndDebtExpense	12000	USD
CY2021	gthp	Inventory Reserve InventoryReserve	0	USD
CY2020	gthp	Inventory Reserve InventoryReserve	-73000	USD
CY2021	us-gaap	Depreciation Depreciation	1000	USD
CY2020	us-gaap	Depreciation Depreciation	0	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	320000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	394000	USD
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8000	USD
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	102000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	228000	USD
CY2020	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	0	USD
CY2021	gthp	Gain From Forgiveness Of Debt GainFromForgivenessOfDebt	578000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	310000	USD
CY2021	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	-448000	USD
CY2020	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	-1879000	USD
CY2021	gthp	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt	0	USD
CY2020	gthp	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt	-296000	USD
CY2021	gthp	Extinguishment Of Derivative Liabilities ExtinguishmentOfDerivativeLiabilities	-84000	USD
CY2020	gthp	Extinguishment Of Derivative Liabilities ExtinguishmentOfDerivativeLiabilities	0	USD
CY2021	gthp	Change In Fair Value Of Derivatives ChangeInFairValueOfDerivatives	-91000	USD
CY2020	gthp	Change In Fair Value Of Derivatives ChangeInFairValueOfDerivatives	-25000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	82000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2021	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	664000	USD
CY2020	gthp	Gain From Forgiveness Of Debt GainFromForgivenessOfDebt	0	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-117000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-33000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	483000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	17000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-18000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	136000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-221000	USD
CY2021	gthp	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	56000	USD
CY2020	gthp	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	296000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-59000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1592000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1875000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	USD
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1248000	USD
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	519000	USD
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-1468000	USD
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-1101000	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	86000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2021	gthp	Note Payable Default Penalty NotePayableDefaultPenalty	398000	USD
CY2020	gthp	Note Payable Default Penalty NotePayableDefaultPenalty	0	USD
CY2021	gthp	Proceeds From Series D Offering Net Of Costs ProceedsFromSeriesDOfferingNetOfCosts	0	USD
CY2020	gthp	Proceeds From Series D Offering Net Of Costs ProceedsFromSeriesDOfferingNetOfCosts	102000	USD
CY2021	gthp	Proceeds From Issuance Of Series E Preferred Stock ProceedsFromIssuanceOfSeriesEPreferredStock	0	USD
CY2020	gthp	Proceeds From Issuance Of Series E Preferred Stock ProceedsFromIssuanceOfSeriesEPreferredStock	1639000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1159000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	461000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-717000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	899000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	643000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Interest Paid InterestPaid	557000	USD
CY2020	us-gaap	Interest Paid InterestPaid	295000	USD
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	361000	USD
CY2020	us-gaap	Dividends Preferred Stock DividendsPreferredStock	122000	USD
CY2021	us-gaap	Notes Issued1 NotesIssued1	323000	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1436000	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2021	gthp	Proceeds From Series F2 Offering Net Of Costs ProceedsFromSeriesF2OfferingNetOfCosts	539000	USD
CY2020	gthp	Proceeds From Series F2 Offering Net Of Costs ProceedsFromSeriesF2OfferingNetOfCosts	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	125000	USD
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2021	gthp	Redemption Of Series G Preferred Stock RedemptionOfSeriesGPreferredStock	-125000	USD
CY2020	gthp	Redemption Of Series G Preferred Stock RedemptionOfSeriesGPreferredStock	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2067000	USD
CY2020	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2021	gthp	Issuance Of Series F2 Preferred Stock IssuanceOfSeriesF2PreferredStock	2236000	USD
CY2020	gthp	Issuance Of Series F2 Preferred Stock IssuanceOfSeriesF2PreferredStock	0	USD
CY2021	gthp	Issuance Of Warrants To Finders In Connection With Series F And Series F2 Preferred Stock IssuanceOfWarrantsToFindersInConnectionWithSeriesFAndSeriesF2PreferredStock	377000	USD
CY2020	gthp	Issuance Of Warrants To Finders In Connection With Series F And Series F2 Preferred Stock IssuanceOfWarrantsToFindersInConnectionWithSeriesFAndSeriesF2PreferredStock	0	USD
CY2021	gthp	Settlement Of Dividends Through Common Stock Issuance SettlementOfDividendsThroughCommonStockIssuance	171000	USD
CY2020	gthp	Settlement Of Dividends Through Common Stock Issuance SettlementOfDividendsThroughCommonStockIssuance	40000	USD
CY2021	gthp	Settlement Of Accounts Payable Through Common Stock Issuance SettlementOfAccountsPayableThroughCommonStockIssuance	62000	USD
CY2020	gthp	Settlement Of Accounts Payable Through Common Stock Issuance SettlementOfAccountsPayableThroughCommonStockIssuance	0	USD
CY2021	gthp	Warrants Exchanged For Fixed Price Warrants WarrantsExchangedForFixedPriceWarrants	1755000	USD
CY2020	gthp	Warrants Exchanged For Fixed Price Warrants WarrantsExchangedForFixedPriceWarrants	131000	USD
CY2021	gthp	Warrants Issued With Debt WarrantsIssuedWithDebt	304000	USD
CY2020	gthp	Warrants Issued With Debt WarrantsIssuedWithDebt	0	USD
CY2021	gthp	Settlement Of Accounts Payable Through Issuance Of Promissory Note SettlementOfAccountsPayableThroughIssuanceOfPromissoryNote	97000	USD
CY2020	gthp	Settlement Of Accounts Payable Through Issuance Of Promissory Note SettlementOfAccountsPayableThroughIssuanceOfPromissoryNote	0	USD
CY2021	gthp	Stock Issued During Period Value Issued For Debt Repayment StockIssuedDuringPeriodValueIssuedForDebtRepayment	0	USD
CY2020	gthp	Stock Issued During Period Value Issued For Debt Repayment StockIssuedDuringPeriodValueIssuedForDebtRepayment	2929000	USD
CY2021	gthp	Conversion Of Preferred Series F To Common Stock ConversionOfPreferredSeriesFToCommonStock	8000	USD
CY2020	gthp	Conversion Of Preferred Series F To Common Stock ConversionOfPreferredSeriesFToCommonStock	0	USD
CY2021	gthp	Increase Decrease In Subscription Receivable IncreaseDecreaseInSubscriptionReceivable	0	USD
CY2020	gthp	Increase Decrease In Subscription Receivable IncreaseDecreaseInSubscriptionReceivable	635000	USD
CY2021	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. </strong><strong>ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2021, the Board simultaneously approved a 1-for-20 reverse stock split of our common stock and decreased the total number of authorized common shares to 500,000,000. On November 18, 2021, the Company submitted an Issuer Company Related Action Notification regarding the reverse stock split to the Financial Industry Regulatory Authority (“FINRA”). FINRA has not yet declared an effective date for the reverse stock split. The Company will adjust the number of shares available for future grant under its equity incentive plan and employee stock purchase plans and will also adjust the number of outstanding awards issued to reflect the effects of its reverse split. All historical share and per share amounts reflected throughout this report will be adjusted to reflect stock split at the time it becomes effective. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis of Presentation </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principals generally accepted in the United States of America, or U.S. GAAP. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of December 31, 2021 and 2020, and the consolidated results of operations and cash flows for the years ended December 31, 2021 and 2020 have been included. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of December 31, 2021, it had an accumulated deficit of approximately $142.4 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision makers are the Chief Executive Officer and its Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At December 31, 2021, the Company had a negative working capital of approximately $4.1 million, accumulated deficit of $142.4 million, and incurred a net loss including preferred dividends of $2.4 million for the year then ended. Stockholders’ deficit totaled approximately $5.4 million at December 31, 2021, primarily due to recurring net losses from operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2021, the Company raised $3.2 million of funds from the sale of preferred stock and 10% convertible debentures. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had warrants exercisable for approximately 27.7 million shares of its common stock outstanding at December 31, 2021, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in-the-money warrants would generate a total of approximately $5.1 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.</p>
CY2021Q4	gthp	Decrease In Authorized Share DecreaseInAuthorizedShare	500000000	shares
CY2021Q4	gthp	Accumulated Deficit AccumulatedDeficit	142400000	USD
CY2021Q4	gthp	Working Capital WorkingCapital	-4100000	USD
CY2021	gthp	Net Loss Including Preferred Dividend NetLossIncludingPreferredDividend	2400000	USD
CY2021Q4	gthp	Total Stockholders Deficits TotalStockholdersDeficits	5400000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Use of Estimates </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of freestanding warrants.</p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Concentrations of Credit Risk</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p>
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1255000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1276000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	69000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	80000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	32000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	785000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	758000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	571000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	605000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1517000	USD
CY2021Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	39000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1761	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1747000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1747	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1746000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	USD
CY2021	gthp	Patent Costs PatentCosts	14800	USD
CY2020	gthp	Patent Costs PatentCosts	17000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	621000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1094000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	98000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	83000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	261000	USD
CY2020Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	34000	USD
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	349000	USD
CY2020Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	202000	USD
CY2021Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	351000	USD
CY2020Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	49000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	65000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1768000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2995000	USD
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	337000	USD
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	42000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	172000	USD
CY2021Q4	gthp	Accounts Receivable Net Of Allowance AccountsReceivableNetOfAllowance	126000	USD
CY2021Q4	us-gaap	Notes Payable NotesPayable	46000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	150000	USD
CY2020Q4	gthp	Accounts Receivable Net Of Allowance AccountsReceivableNetOfAllowance	126000	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	24000	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	61600000	USD
CY2021	gthp	Warrants Warrants	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Warrants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.</p>
CY2021Q4	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	400000	USD
CY2021Q4	us-gaap	Derivative Liability Fair Value Of Collateral DerivativeLiabilityFairValueOfCollateral	700000	USD
CY2021	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	1100000	USD
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	-32000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	-2228000	USD
CY2021	gthp	Summary Of Changes To Level3 Instruments SummaryOfChangesToLevel3Instruments	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(in thousands)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Senior Secured Debt</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Derivative</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance, December 31, 2020</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,203</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,228</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in the terms of warrants previously recorded as a liability and now reclassified to equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,755</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,755</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in value due to warrants expiring during the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">448</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">448</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">84</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">84</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in fair value during the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(91</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(91</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance, December 31, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(32</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(32</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></tbody></table>
CY2021Q4	gthp	Common Stock Shares Authorized Shares CommonStockSharesAuthorizedShares	500000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	13673583	shares
CY2020Q4	gthp	Common Stocks Shares Outstanding CommonStocksSharesOutstanding	13138282	shares
CY2020	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	9818813	shares
CY2021	gthp	Schedule Common Stock Issued Table Textblock ScheduleCommonStockIssuedTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="5" style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of debt into common shares - exchange agreements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,957,013</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of debt into common shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">175,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued for manufacturing agreements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,147</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued for payment of Series D dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,653</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued to investors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,526,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued during the year ended December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,818,813</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued for payment of Series D dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,039</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued for payment of Series E dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">288,262</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares issued for payment of finder fee</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">98,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series F Preferred shares into common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued during the year ended December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">535,301</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Summary table of common stock share transactions:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,319,469</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued in 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,818,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,138,282</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued in 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">535,301</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,673,583</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2020	gthp	Stock Issued During Period Shares Issued For Conversion Of Debt Exchange Agreements StockIssuedDuringPeriodSharesIssuedForConversionOfDebtExchangeAgreements	7957013	shares
CY2020	gthp	Stock Issued During Period Shares Issued For Conversion Of Debt StockIssuedDuringPeriodSharesIssuedForConversionOfDebt	175000	shares
CY2020	gthp	Stock Issued During Period Shares Issued For Manufacturing Agreements StockIssuedDuringPeriodSharesIssuedForManufacturingAgreements	12147	shares
CY2020	gthp	Stock Issued During Period Shares Issued For Series D Dividends StockIssuedDuringPeriodSharesIssuedForSeriesDDividends	148653	shares
CY2020	gthp	Stock Issued During Period Shares Issued For Investments StockIssuedDuringPeriodSharesIssuedForInvestments	1526000	shares
CY2020	gthp	Stock Issued During Period StockIssuedDuringPeriod	9818813	shares
CY2021	gthp	Stock Issued During Period Shares Issued For Series D Dividends StockIssuedDuringPeriodSharesIssuedForSeriesDDividends	109039	shares
CY2021	gthp	Stock Issued During Period Shares Issued For Series E Dividends StockIssuedDuringPeriodSharesIssuedForSeriesEDividends	288262	shares
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	98000	shares
CY2021	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	40000	shares
CY2021	gthp	Stock Issued During Period StockIssuedDuringPeriod	535301	shares
CY2019	gthp	Shares Outstanding One SharesOutstandingOne	3319469	shares
CY2020	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	9818813	shares
CY2020	gthp	Shares Outstanding One SharesOutstandingOne	13138282	shares
CY2021Q4	gthp	Warrant Warrant	3592500	shares
CY2021	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	535301	shares
CY2021	gthp	Shares Outstanding One SharesOutstandingOne	13673583	shares
CY2021	gthp	Debt Conversion Converted Instrument Warrants Issued4 DebtConversionConvertedInstrumentWarrantsIssued4	700000	shares
CY2021	gthp	Debt Conversion Converted Instrument Warrants Issued5 DebtConversionConvertedInstrumentWarrantsIssued5	250000	shares
CY2021Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	2737847	USD
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2496316	USD
CY2021Q4	gthp	Debt Instrument Accrued Interest DebtInstrumentAccruedInterest	241531	USD
CY2021	gthp	Common Stock Shares CommonStockShares	7957013	shares
CY2021	gthp	Debt Conversion Converted Instrument Warrants Issued3 DebtConversionConvertedInstrumentWarrantsIssued3	4713603	shares
CY2021	gthp	Debt Conversion Converted Instrument Warrants Issued1 DebtConversionConvertedInstrumentWarrantsIssued1	1121705	shares
CY2021	gthp	Debt Conversion Converted Instrument Warrants Issued2 DebtConversionConvertedInstrumentWarrantsIssued2	1121705	shares
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	3262	shares
CY2021Q4	us-gaap	Shares Outstanding SharesOutstanding	1049	shares
CY2021	gthp	Schedule Shares Reserved For Warrants Table Textblock ScheduleSharesReservedForWarrantsTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Warrants </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(Underlying Shares)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted-Average Exercise Price Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding, January 1, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46,016,840</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.71</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Warrants issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,270,013</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Warrants cancelled/expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,068,423</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Warrants exchanged</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(28,962,508</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.04</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding, December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,324,275</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Warrants issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,982,223</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.30</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Warrants cancelled/expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,729,662</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.04</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Warrants exchanged</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,713,603</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.20</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Warrants exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,193,599</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding, December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">27,669,634</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.29</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	46016840	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.71
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	11270013	shares
CY2020	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.34
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	70	shares
CY2020	gthp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExchanged	-28962508	USD
CY2020	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options For Exchange In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangeInPeriodWeightedAverageExercisePrice	0.04
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	28324275	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.25
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	7982223	shares
CY2021	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.30
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	1729662	shares
CY2021	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired	0.04
CY2021	gthp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExchanged	-4713603	USD
CY2021	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options For Exchange In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangeInPeriodWeightedAverageExercisePrice	0.20
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2193599	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.16
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	27669634	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2021	gthp	Schedule Of Fair Value Warrants Issued Under Black Scholes Option Pricing Model Table Textblock ScheduleOfFairValueWarrantsIssuedUnderBlackScholesOptionPricingModelTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected term</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15 days</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">143.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P15Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.432	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021Q4	gthp	Financing Amount FinancingAmount	4000000.0	USD
CY2021Q4	gthp	Common Stock Warrants CommonStockWarrants	7185000	shares
CY2021Q4	gthp	Warrants Price Per Share WarrantsPricePerShare	0.20
CY2021Q4	gthp	Cash Payment CashPayment	350000	USD
CY2021Q4	gthp	Successful In Obtaining Financing Greater Than Amount SuccessfulInObtainingFinancingGreaterThanAmount	4000000.0	USD
CY2021Q4	gthp	Warrants Closing Of Financing Greater Than Amount WarrantsClosingOfFinancingGreaterThanAmount	4000000.0	USD
CY2021	gthp	Warrant Holders Percentage Description WarrantHoldersPercentageDescription	4.99% blocker such that the warrant holders will be restricted from owning more than 4.99% of the total number
CY2021Q4	gthp	Warratns Issued WarratnsIssued	263000	shares
CY2021Q4	gthp	Additional Warrants To Purchase Common Stock Shares AdditionalWarrantsToPurchaseCommonStockShares	150000	shares
CY2021	gthp	Additional Warrants To Purchase Common Stock Shares Expire Date AdditionalWarrantsToPurchaseCommonStockSharesExpireDate	2024-05-31
CY2021Q4	gthp	Issued Equity Investments IssuedEquityInvestments	2114000	USD
CY2021Q4	gthp	Issued Common Stock Shares To Finders IssuedCommonStockSharesToFinders	98000	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	35937500	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.04
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	7185000	shares
CY2020Q1	gthp	Issuance Of New Warrants To Purchase Shares Of Common Stock Exercise Price IssuanceOfNewWarrantsToPurchaseSharesOfCommonStockExercisePrice	0.20
CY2021	us-gaap	Payments For Rent PaymentsForRent	750000	USD
CY2021	gthp	Finder Compensation In Percentage FinderCompensationInPercentage	The finder will receive 5% cash and 5% warrants on all funds it raises including bridge loans. The three-year common stock share warrants will have an exercise price of $0.25.
CY2021Q4	gthp	Raise Funds RaiseFunds	300000	USD
CY2021	us-gaap	Payments For Fees PaymentsForFees	31650	USD
CY2021Q4	gthp	Warrants Issued To Finder WarrantsIssuedToFinder	126600	shares
CY2020Q1	gthp	Warratns Issued WarratnsIssued	5000000	shares
CY2020Q1	gthp	Strike Price Of Warrants StrikePriceOfWarrants	0.25
CY2020Q1	gthp	Common Stock Warrants CommonStockWarrants	1250000	shares
CY2020Q1	gthp	Common Stock Share Price CommonStockSharePrice	0.50
CY2020Q1	gthp	Additional Warrants To Purchase Common Stock Shares AdditionalWarrantsToPurchaseCommonStockShares	1250000	shares
CY2020Q1	gthp	Additional Warrants To Purchase Common Stock Shares Price AdditionalWarrantsToPurchaseCommonStockSharesPrice	1.00
CY2020Q1	gthp	Additional Common Stock Warrants AdditionalCommonStockWarrants	1250000	shares
CY2020Q1	gthp	Additional Common Stock Warrants Price Per Share AdditionalCommonStockWarrantsPricePerShare	1.25
CY2021	gthp	Warrants Holders Percentage Description WarrantsHoldersPercentageDescription	The consultant agrees to a 10.0% blocker at any single point in time it cannot own 10.0% of the total common stock shares outstanding. The Company issued 1,250,000 common stock warrants during the year ended December 31, 2021, in accordance with the agreement. Refer to Note 7, “Commitments and Contingencies” for additional information.
CY2021	gthp	Options Granted Exercisable Term OptionsGrantedExercisableTerm	four years
CY2021	gthp	Options Granted Expiration Term OptionsGrantedExpirationTerm	ten years
CY2021Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.10	pure
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	226717	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	309905	USD
CY2021	gthp	Outstanding At Beginning Of Year OutstandingAtBeginningOfYear	1800000	shares
CY2020Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.49
CY2021	gthp	Options Granted OptionsGranted	25000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.48
CY2021	gthp	Share Based Compensation Arrangement By Share Based Payment Award Option Forfeiture In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeitureInPeriod	-167614	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.49
CY2021	gthp	Share Based Compensation Arrangement By Share Based Payment Award Option Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriod	-157386	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.49
CY2021	gthp	Outstanding End OutstandingEnd	1500000	shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.49
CY2021	gthp	Weighted Average Remaining Contractual Life Outstanding WeightedAverageRemainingContractualLifeOutstanding	P8Y6M
CY2021	gthp	Agrregate Intrensic Value Outstanding AgrregateIntrensicValueOutstanding	135	USD
CY2021	gthp	Number Of Shares Exercisable NumberOfSharesExercisable	954273	shares
CY2021	gthp	Weighted Average Exercise Price Per Share Exercisable WeightedAverageExercisePricePerShareExercisable	0.49
CY2021	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P8Y6M
CY2021	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	86	USD
CY2021	gthp	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	263470	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.48
CY2021	gthp	Expected Term Years ExpectedTermYears	P10Y
CY2020	gthp	Expected Term Years ExpectedTermYears	P10Y
CY2021	gthp	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	1.5312	pure
CY2020	gthp	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	1.5312	pure
CY2021	gthp	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0098	pure
CY2020	gthp	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0098	pure
CY2021	gthp	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0.0000	pure
CY2020	gthp	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0.0000	pure
CY2020Q4	gthp	Notes Payable In Default Including Related Parties Others NotesPayableInDefaultIncludingRelatedPartiesOthers	329000	USD
CY2021Q3	us-gaap	Notes And Loans Payable NotesAndLoansPayable	285244	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32945	USD
CY2009Q4	gthp	Area Of Operating Leases AreaOfOperatingLeases	12,835
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	110701	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	114591	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	372000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	392000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	108000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	112000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	115000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	118000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	50000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	503000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	111000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	392000	USD
CY2021	gthp	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	P4Y4M24D
CY2021	gthp	Weighted Average Discount Rateoperating Lease WeightedAverageDiscountRateoperatingLease	0.114	pure
CY2016Q2	gthp	Royalty Percent RoyaltyPercent	20
CY2016Q2	gthp	Licences Licences	1000000.0	USD
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5000000	shares
CY2020Q1	gthp	Warrants Broken Into Four Tranches WarrantsBrokenIntoFourTranches	1250000	shares
CY2020Q1	gthp	Net Loss Increased NetLossIncreased	318000	USD
CY2021Q4	gthp	Financing Agreement Amount FinancingAgreementAmount	1000000	USD
CY2019Q3	gthp	Consideration Received ConsiderationReceived	885144	USD
CY2021Q4	gthp	Notes Payable In Default NotesPayableInDefault	0	USD
CY2020Q4	gthp	Notes Payable In Default NotesPayableInDefault	329000	USD
CY2021Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	27000	USD
CY2020Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	329000	USD
CY2021Q4	gthp	Short Term Notes Payable ShortTermNotesPayable	165000	USD
CY2020Q4	gthp	Short Term Notes Payable ShortTermNotesPayable	96000	USD
CY2021	gthp	Annual Interest Rate Description One AnnualInterestRateDescriptionOne	The notes carry annual interest rates between 4.3% and 6% (16% to 18% in the event of default).
CY2021Q4	gthp	Short Term Note Payable Including Related Parties ShortTermNotePayableIncludingRelatedParties	88000	USD
CY2020Q4	gthp	Short Term Note Payable Including Related Parties ShortTermNotePayableIncludingRelatedParties	96000	USD
CY2021Q4	gthp	Short Term Notes Payable Including Related Parties ShortTermNotesPayableIncludingRelatedParties	88000	USD
CY2020Q4	gthp	Short Term Notes Payable Including Related Parties ShortTermNotesPayableIncludingRelatedParties	96000	USD
CY2020	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	10767	shares
CY2021	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.18
CY2020	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.04
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13377	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	10767	shares
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.18
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36739	shares
CY2020Q4	gthp	Convertible Notes Payable In Default ConvertibleNotesPayableInDefault	1930000	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	69778	shares
CY2021	gthp	Troubled Debt Restructuring Description TroubledDebtRestructuringDescription	the troubled debt restructuring in total would have decreased the net loss by $85,000, causing the per share calculation to change from .18 to .19 net loss per share.
CY2021	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	94392	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	58000000.0	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	9900000	USD
CY2021	gthp	Taxable Income Offset TaxableIncomeOffset	0.80	pure
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-14000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-262000	USD
CY2021Q4	gthp	Convertible Notes Payable Short Term ConvertibleNotesPayableShortTerm	897000	USD
CY2020Q4	gthp	Convertible Notes Payable Short Term ConvertibleNotesPayableShortTerm	951000	USD
CY2021Q4	gthp	Convertible Notes Payable In Default ConvertibleNotesPayableInDefault	0	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2431000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-401000	USD
CY2021	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	13377	shares
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.25	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.25	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1728000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1623000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1728000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1623000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	617000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	288000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	519000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	273000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	289000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	134000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	132000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16985000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17851000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17680000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19408000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17680000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19408000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4477923	shares

Files In Submission

Name	View Source	Status
0001477932-22-001704-index-headers.html	Edgar Link	pending
0001477932-22-001704-index.html	Edgar Link	pending
0001477932-22-001704.txt	Edgar Link	pending
0001477932-22-001704-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gthp-20211231.xsd	Edgar Link	pending
gthp-20211231_cal.xml	Edgar Link	unprocessable
gthp-20211231_def.xml	Edgar Link	unprocessable
gthp-20211231_lab.xml	Edgar Link	unprocessable
gthp-20211231_pre.xml	Edgar Link	unprocessable
gthp_10k.htm	Edgar Link	pending
gthp_10k_htm.xml	Edgar Link	completed
gthp_ex1073.htm	Edgar Link	pending
gthp_ex1074.htm	Edgar Link	pending
gthp_ex1075.htm	Edgar Link	pending
gthp_ex1076.htm	Edgar Link	pending
gthp_ex1077.htm	Edgar Link	pending
gthp_ex1078.htm	Edgar Link	pending
gthp_ex1079.htm	Edgar Link	pending
gthp_ex1080.htm	Edgar Link	pending
gthp_ex1081.htm	Edgar Link	pending
gthp_ex1082.htm	Edgar Link	pending
gthp_ex1083.htm	Edgar Link	pending
gthp_ex1084.htm	Edgar Link	pending
gthp_ex1085.htm	Edgar Link	pending
gthp_ex1086.htm	Edgar Link	pending
gthp_ex1087.htm	Edgar Link	pending
gthp_ex1087img55.gif	Edgar Link	pending
gthp_ex1088.htm	Edgar Link	pending
gthp_ex231.htm	Edgar Link	pending
gthp_ex31.htm	Edgar Link	pending
gthp_ex32.htm	Edgar Link	pending
gthp_ex38.htm	Edgar Link	pending
gthp_ex446.htm	Edgar Link	pending
gthp_ex447.htm	Edgar Link	pending
gthp_ex448.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

2021 Q4 Form 10-K Financial Statement

#000147793222001704 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP GUIDED THERAPEUTICS INC Stock $gthp

2021 Q4 Form 10-K Financial Statement

#000147793222001704 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp